ClinicalTrials.gg
Not yet recruitingNCT07878091Updated Oct 16, 2026

A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)

A Phase 2 interventional study of Kylo 0603 Capsule 8mg and Kylo 0603 Capsule 12mg in Metabolic Dysfunction-Associated Steatoic Liver Disease, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Updated Oct 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic stress-related liver injury closely associated with insulin resistance, with a global prevalence of approximately 25%. It may progress to metabolic dysfunction-associated steatohepatitis (MASH), which can lead to cirrhosis, end-stage liver disease, and increased cardiovascular risk, representing a major unmet medical need. Thyroid hormone receptor beta (THRβ) is predominantly expressed in the liver; selective agonism regulates hepatic lipid metabolism, reduces fat accumulation, suppresses hepatic inflammation and fibrosis, and may delay MASH progression. Kylo-0603 is a liver-targeted, highly selective THRβ agonist modified with GalNAc to enrich hepatic exposure and reduce peripheral effects. This multicenter, randomized, double-blind, placebo-controlled Phase 2a study will evaluate the efficacy, safety, and pharmacokinetics of once-daily oral Kylo-0603 capsules in approximately 120 participants with MASLD and overweight or obesity. Participants will be randomized 1:1:1:1 to Kylo-0603 8 mg, 12 mg, 16 mg, or placebo for 12 weeks. The primary endpoint is the percentage change from baseline in liver fat content assessed by MRI-PDFF at Week 12.

02

Conditions studied

  • Metabolic Dysfunction-Associated Steatoic Liver Disease
03

In context

Lead sponsor

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. is the lead sponsor of 18 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following inclusion criteria to be eligible for this study:
  • Age between 18 and 70 years, inclusive.
  • Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) ≥ 10% at screening.
  • Body weight stable within 6 weeks before screening (absolute change in body weight ≤ 5%).
  • Liver stiffness measurement (LSM) by FibroScan at screening: 8 kPa ≤ LSM \< 15 kPa.
  • (BMI) between 25.0 and 40.0 kg/m², inclusive, at screening.
  • Participants must have no childbearing plans during the study and for 6 months after the last dose, and must voluntarily use effective measures.
  • No alcohol consumption or no history of excessive alcohol consumption. A history of excessive alcohol consumption is defined as: in the past 12 months, weekly ethanol (alcohol) intake ≥ 210 g for men and ≥ 140 g for women. Ethanol intake (g) = alcohol consumption volume (mL) × alcohol by volume (%) × 0.8.
  • Participants must voluntarily participate in the clinical trial, be able to sign the form (ICF), and be able to understand and comply with the trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Chronic liver disease of other etiologies, including viral hepatitis ( virus [HBV], virus [HCV]), (HIV), syphilis, primary sclerosing cholangitis, primary biliary cholangitis, hepatitis, drug-induced liver disease, alcoholic liver disease, Wilson disease, or other etiologies judged by the investigator.
  • History of liver transplantation or planned liver transplantation.
  • Confirmed or suspected cirrhosis, or current or previous hepatic decompensation, including portal hypertension (e.g., esophageal varices, ascites) or hepatic encephalopathy.
  • History of thyroid disease, current use of drugs affecting thyroid function, positive thyroid-related antibodies, or abnormal thyroid function tests at screening. Thyroid-related antibodies include anti-thyroid peroxidase antibody (TPOAb), thyroid-stimulating hormone receptor antibody (TRAb), and anti-thyroglobulin antibody (TGAb). Thyroid function tests include thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), total triiodothyronine (TT3), and total thyroxine (TT4).
  • Diabetes other than type 2 diabetes mellitus; poor glycemic control ( [HbA1c] >= 9% or fasting plasma glucose >= 13.9 mmol/L); need for additional glucose-lowering therapy during the study; or history of severe hypoglycemia.
  • History of bariatric surgery within 5 years before screening.
  • Use of medications that may cause hepatic steatosis, steatohepatitis, or hepatotoxicity within 12 months before screening, including but not limited to valproic acid, tamoxifen, methotrexate, amiodarone, oral > 5 mg/day prednisone or equivalent, or estrogens at doses greater than those used for or hormone replacement.
  • Receipt of insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, or glucagon receptor (GCGR) agonists within 6 months before screening.
  • Use of weight-loss medications within 6 months before screening or planned use during the study.
  • Current or recent use of approved metabolic dysfunction-associated steatohepatitis (MASH) therapies, or participation in another MASH clinical trial within 6 months or 5 half-lives before screening, whichever is longer.
  • Use of hepatoprotective drugs within 4 weeks before screening or planned use during the study.
  • Unstable doses of vitamin E, osteoporosis therapies, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones, statins, fibrates, or other glucose-lowering, weight-affecting, or lipid-modifying drugs within the specified period before screening.
  • Poorly controlled hypertension, defined as systolic blood pressure (SBP) >= 160 mmHg or diastolic blood pressure (DBP) >= 100 mmHg based on the mean of 3 measurements at screening.
  • History of within 5 years before screening, or active or suspected malignancy under evaluation at screening. Adequately treated basal cell carcinoma, squamous cell skin cancer, and carcinoma in situ of the cervix are excluded.
  • Major surgery within 3 months before signing the form (ICF), or planned major surgery during the study.
  • History of drug abuse within 1 year before screening.
  • Participation in another clinical trial of an approved or unapproved drug or device within 3 months or 5 half-lives before screening, whichever is longer.
  • Known or suspected intolerance or allergy to the investigational drug, its , or drugs with the same target.
  • Abnormal laboratory values at screening: (ALT) or aspartate aminotransferase (AST) > 5 x (ULN); alkaline phosphatase (ALP) >= 2 x ULN; estimated (eGFR) \< 60 mL/min/1.73 m2; (INR) >= 1.3; total > 1.5 x ULN; or count \< lower limit of normal (LLN).
  • Blood transfusion within 2 months before screening, blood donation within 1 month before screening, breastfeeding, or positive pregnancy test in female participants.
  • Significant systemic or major diseases other than liver disease, including recent (within 6 months before screening) congestive heart failure ( [NYHA] functional class III-IV), unstable coronary artery disease, arterial revascularization, respiratory disease, renal failure, stroke, , organ transplantation, psychiatric disorders, or any disease-related event requiring hospitalization.
  • to magnetic resonance imaging (MRI); clinically significant (ECG) abnormalities, including Fridericia's formula- interval (QTcF) >= 450 msec in men or >= 470 msec in women at screening; or any condition that, in the investigator's opinion, may increase safety risk or interfere with study participation or compliance.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Test group: Kylo-0603 Capsules 8mg

    Kylo 0603 capsule 8 mg,administered for 12 weeks

    Drug: Kylo 0603 Capsule 8mg

  • Experimental
    Test group: Kylo-0603 Capsules 12mg

    Kylo 0603 capsule 12 mg, administered for 12 weeks

    Drug: Kylo 0603 Capsule 12mg

  • Experimental
    Test group: Kylo-0603 Capsules 16mg

    Kylo 0603 capsule 16 mg, administered for 12 weeks

    Drug: Kylo 0603 Capsule 16mg

  • Placebo comparator
    Control Group: Kylo 0603 Capsule Placebo

    Kylo 0603 Capsules placebo, administered for 12 weeks

    Drug: Kylo 0603 Capsule Placebo

Interventions

  • DrugKylo 0603 Capsule 8mg

    THR β agonist

  • DrugKylo 0603 Capsule 12mg

    THR β agonist

  • DrugKylo 0603 Capsule 16mg

    THR β agonist

  • DrugKylo 0603 Capsule Placebo

    Placebo

06

What researchers measure

Primary outcomes

  1. The percentage change from baseline in liver fat content

    The percentage change from baseline in liver fat content assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) after 12 weeks of treatment.

    Time frame: After 12 weeks of treatment.

Secondary outcomes

  1. Change in Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFFZ)

    Change from baseline in MRI-PDFF

    Time frame: After 12 weeks of treatment

  2. Proportion of participants with a decrease in Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)

    Proportion of Study Participants with ≥30% and 50% reduction in MRI-PDFF from baseline

    Time frame: After 12 weeks of treatment.

  3. Change from baseline in liver stiffness measurement (LSM)

    Time frame: After 12 weeks of treatment.

  4. Change in low-density lipoprotein cholesterol (LDL-c)

    Time frame: After 12 weeks of treatment.

  5. Change from baseline in alanine aminotransferase (ALT)

    Time frame: After 12 weeks of treatment.

  6. High-sensitivity C-reactive protein (hsCRP)

    Time frame: After 12 weeks of treatment.

  7. Change from baseline in cytokeratin-18 (CK-18)

    Time frame: After 12 weeks of treatment.

  8. Change in body mass index [BMI]

    Time frame: After 12 weeks of treatment.

  9. Change in the level of insulin resistance

    Change from baseline in the level of insulin resistance: assessed by the Homeostasis Model Assessment (HOMA-IR)

    Time frame: After 12 weeks of treatment.

  10. Percentage change from baseline in sex hormone-binding globulin (SHBG)

    Time frame: After 12 weeks of treatment.

  11. Incidence of adverse events

    Time frame: From enrollment to the end of 12 weeks

  12. maximum plasma concentration (Cmax) of Kylo-0603

    Time frame: From administration to the end of 12 weeks

  13. Percentage change from baseline in controlled attenuation parameter (CAP) assessed by FibroScan

    Time frame: After 12 weeks of treatment.

  14. Change from baseline in aspartate aminotransferase (AST)

    Time frame: After 12 weeks of treatment.

  15. Change from baseline in high-density lipoprotein cholesterol (HDL-c)

    Time frame: After 12 weeks of treatment.

  16. Change from baseline in non-high-density lipoprotein cholesterol (non-HDL-c)

    Time frame: After 12 weeks of treatment.

  17. Change from baseline in total cholesterol (TC)

    Time frame: After 12 weeks of treatment.

  18. Change from baseline in triglyceride

    Time frame: After 12 weeks of treatment.

  19. Change from baseline in the liver fibrosis marker FIB-4 score

    Time frame: After 12 weeks of treatment.

  20. Change from baseline in the Enhanced Liver Fibrosis (ELF) test

    Time frame: After 12 weeks of treatment.

  21. Change from baseline in the AST to Platelet Ratio Index (APRI) score

    Time frame: After 12 weeks of treatment.

07

Study locations

1 site
  • Beijing Tsinghua Changgung Hospital, Affiliated to Tsinghua University
    Beijing, Beijing Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 16, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Aug 15, 2027
CompletionEst.
Aug 15, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07878091
Responsible party
Sponsor
First posted
Oct 16, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Aug 15, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Lai Wei, Doctor
Contact
weilai@163.com
13601281862

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion